Eur. Urol. 2020 Jan 27
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A
Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspect ...
Read More
Source: PubMed
Ann. Oncol.
Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?
Belderbos BPS, de Wit R, Lolkema MPJ, Mathijssen RHJ, van Soest RJ
Androgen-deprivation therapy (ADT) has been the mainstay of treatment of metastatic prostate cancer since the first report of its hormonal dependence ...
Read More
Source: PubMed
Cancer J
Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
Kinsey EN, Zhang T, Armstrong AJ
In recent years, the treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded significantly. In addition to androgen d ...
Read More
Source: PubMed
Cancer J
Surrogate Endpoints in Localized Prostate Cancer.
Hartman HE, Jackson WC
Randomized clinical trials assessing novel therapies in men with localized prostate cancer frequently require large patient numbers and more than a de ...
Read More
Source: PubMed
Cancer 2020 Jan 24
Physician and facility drivers of spending variation in locoregional prostate cancer.
Rodin D, Chien AT, Ellimoottil C, Nguyen PL, Kakani P, Mossanen M, Rosenthal M, Landrum MB, Sinaiko AD
Prostate cancer is the most common male cancer, with a wide range of treatment options. Payment reform to reduce unnecessary spending variation is an ...
Read More
Source: PubMed
